Federal Register Reported FDA Announcing Revocation Of EUAs Issued To Bio-Rad Laboratories For The Bio-Rad Sars-Cov-2 DDPCR Kit
Portfolio Pulse from Charles Gross
The FDA has announced the revocation of Emergency Use Authorizations (EUAs) issued to Bio-Rad Laboratories for their Bio-Rad Sars-Cov-2 DDPCR Kit.
May 17, 2024 | 11:04 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
The FDA has revoked the Emergency Use Authorizations (EUAs) for Bio-Rad Laboratories' Sars-Cov-2 DDPCR Kit, which could negatively impact the company's stock price in the short term.
The revocation of EUAs by the FDA directly affects Bio-Rad Laboratories' product line, potentially leading to a decrease in investor confidence and a short-term drop in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100